Spero Therapeutics, Inc. Income Statement
SPRO|8 years of annual SEC 10-K data (FY2018-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 8 fiscal years. All figures from audited SEC 10-K filings.
Spero Therapeutics, Inc. reported $48M in revenue and $69M in net loss for FY2025. Revenue has grown at a 103.2% compound annual rate over the past 7 years.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -1.15 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $48.0M | $103.8M | $53.5M | $18.3M | $9.3M | $18.1M | $4.0M | $335.0K |
| SG&A Expense | $23.7M | $25.6M | $36.5M | $41.7M | $21.4M | $15.6M | $12.9M | $7.2M |
| R&D Expense | $96.8M | $51.4M | $47.6M | $64.5M | $67.0M | $65.8M | $33.9M | $26.3M |
| Operating Income | -$73.4M | $21.5M | -$42.2M | -$88.0M | -$79.1M | -$63.2M | -$42.8M | -$33.2M |
| Income Tax | $0 | $2.6M | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$68.6M | $22.8M | -$46.4M | -$89.8M | -$78.3M | -$60.9M | -$41.7M | -$25.5M |
| EPS (Basic) | -$1.27 | $0.43 | -$1.23 | -$2.91 | - | - | - | - |
| EPS (Diluted) | -$1.27 | $0.43 | -$1.23 | -$2.91 | -$3.52 | -$3.35 | -$2.60 | -$95.87 |
| Shares Outstanding | 54.6M | 53.0M | 52.5M | 32.4M | 29.3M | 19.2M | 17.2M | 14.4M |
| Operating Margin | -152.9% | 20.7% | -78.9% | -481.9% | -847.9% | -348.4% | -1079.3% | -9916.7% |
| Profit Margin | -142.9% | 22.0% | -86.7% | -491.7% | -839.2% | -335.6% | -1051.4% | -7609.3% |